Is Shanghai Hyundai Pharmaceutical a state-owned enterprise or a central enterprise?

Shanghai Hyundai Pharmaceutical is a central enterprise. The full name of Shanghai Hyundai Pharmaceutical Co., Ltd. is Shanghai Hyundai Pharmaceutical Co., Ltd., which was established in 1996. Is a high-tech enterprise specializing in research and development, production and sales of pharmaceutical products.

Shanghai Hyundai Pharmaceutical Co., Ltd. is a high-tech pharmaceutical enterprise with the purpose of listing, with Shanghai Pharmaceutical Industry Research Institute as the main sponsor and five enterprises including National Pharmaceutical Preparation Engineering Research Center and Shanghai Ruijin Hospital Guangci Medical High-tech Company.

Company listing

The company was listed on the Shanghai Stock Exchange on June 16, 2004 (code: 600420). 20 10 entered China pharmaceutical group co., ltd in April 20 16-20 18. according to the decision-making arrangements of SASAC and sinopharm group, the company successfully completed the reorganization and integration of the chemical sector. The reorganized company has been merged into the industrial product line and enterprise assets of the chemical sector of Sinopharm Group, forming a market subject with more efficient resource planning and clearer main business operation.

Company size

At present, the company has 23 wholly-owned and holding companies, including two-level enterprises 13, three-level and four-level enterprises 10, and five production bases10/provinces and cities all over the country.

Company development concept

The company adheres to the strategic positioning of "one body and two wings" with the chemical pharmaceutical industry as the main body, biopharmaceuticals and big health business as the two wings, adheres to the corporate philosophy of "protecting life and caring for health", focuses on five major fields of "anti-infection, cardiovascular and cerebrovascular diseases, anti-tumor, metabolism and endocrine, and anesthesia", coordinates and optimizes the industrial layout, realizes healthy and stable development through multi-wheel drive, and is committed to becoming an innovation-driven enterprise.

Company development direction

The company is positioned as a unified chemical and pharmaceutical industry platform under Sinopharm Group, with 23 wholly-owned and holding subsidiaries, including 5 secondary subsidiaries/KLOC-0 and 8 tertiary subsidiaries. It has formed a specialized strategic development pattern with unified strategy, concentrated resources, reasonable allocation, scale effect and industrial chain linkage effect, and its main business income has exceeded 10 billion.

Business scope of the company

Pharmaceutical and health care products manufacturing, sales of pharmaceuticals, medicinal raw materials, cosmetics, health care products and medical supplies, medical equipment management, medical technology, beauty technology, health care products technology, medical equipment technology development, technology transfer, technical consultation, technical services, wholesale sales of pharmaceutical machinery, import and export of goods or technologies, lease of own equipment and lease of own houses. Projects that must be approved according to law can only carry out business activities after being approved by the relevant departments.